Evidence map›Paper›PMID 34995294›Full record

ArticlePloS one2022

Association of genetic variations in ACE2, TIRAP and factor X with outcomes in COVID-19.

Marissa J M Traets, Roel H T Nijhuis, Servaas A Morré, Sander Ouburg, Jasper A Remijn, Bastiaan A Blok, Bas de Laat, Eefje Jong, Gerarda J M Herder, Aernoud T L Fiolet and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 3 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 3 syntheses or guidelines pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Marissa J M TraetsMeander Medical Centre, Department of Internal Medicine, Amersfoort, The Netherlands.ORCID 0000-0003-0821-7995
Roel H T NijhuisMeander Medical Centre, Department of Medical Microbiology and Medical Immunology, Amersfoort, The Netherlands.ORCID 0000-0003-4203-3858
Servaas A MorréDepartment of Medical Microbiology and Infection Control, Laboratory of Immunogenetics, Amsterdam UMC, Amsterdam, The Netherlands.
Sander OuburgDepartment of Medical Microbiology and Infection Control, Laboratory of Immunogenetics, Amsterdam UMC, Amsterdam, The Netherlands.
Jasper A RemijnMeander Medical Centre, Department of Clinical Chemistry, Amersfoort, The Netherlands.ORCID 0000-0003-3004-3549
Bastiaan A BlokMeander Medical Centre, Department of Internal Medicine, Amersfoort, The Netherlands.
Bas de LaatSynapse Research Institute, Maastricht, The Netherlands.
Eefje JongMeander Medical Centre, Department of Internal Medicine, Amersfoort, The Netherlands.
Gerarda J M HerderMeander Medical Centre, Department of Pulmonary Disease, Amersfoort, The Netherlands.
Aernoud T L FioletMeander Medical Centre, Department of Internal Medicine, Amersfoort, The Netherlands.
Stephan P VerweijMeander Medical Centre, Department of Internal Medicine, Amersfoort, The Netherlands.
Meander Medisch Centrum · NLAmsterdam University Medical Centers · NLMaastricht University · NLSynapse (Netherlands) · NLUniversity Medical Center Utrecht · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCoronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), can manifest with varying disease severity and mortality. Genetic predisposition influences the clinical course of infectious diseases. We investigated whether genetic polymorphisms in candidate genes ACE2, TIRAP, and factor X are associated with clinical outcomes in COVID-19.

methodsWe conducted a single-centre retrospective cohort study. All patients who visited the emergency department with SARS-CoV-2 infection proven by polymerase chain reaction were included. Single nucleotide polymorphisms in ACE2 (rs2285666), TIRAP (rs8177374) and factor X (rs3211783) were assessed. The outcomes were mortality, respiratory failure and venous thromboembolism. Respiratory failure was defined as the necessity of >5 litres/minute oxygen, high flow nasal oxygen suppletion or mechanical ventilation.

resultsBetween March and April 2020, 116 patients (35% female, median age 65 [inter quartile range 55-75] years) were included and treated according to the then applicable guidelines. Sixteen patients (14%) died, 44 patients (38%) had respiratory failure of whom 23 required endotracheal intubation for mechanical ventilation, and 20 patients (17%) developed venous thromboembolism. The percentage of TIRAP polymorphism carriers in the survivor group was 28% as compared to 0% in the non-survivor group (p = 0.01, Bonferroni corrected p = 0.02). Genotype distribution of ACE2 and factor X did not differ between survivors and non-survivors.

conclusionThis study shows that carriage of TIRAP polymorphism rs8177374 could be associated with a significantly lower mortality in COVID-19. This TIRAP polymorphism may be an important predictor in the outcome of COVID-19.

Indexed as

AgedAngiotensin-Converting Enzyme 2Cohort StudiesCOVID-19Factor XFemaleGenetic Predisposition to DiseaseGenotypeHumansMaleMembrane GlycoproteinsMiddle AgedNetherlandsPolymorphism, Single NucleotideReceptors, Interleukin-1Retrospective StudiesACE2 protein, humanAngiotensin-Converting Enzyme 2Factor XMembrane GlycoproteinsReceptors, Interleukin-1TIRAP protein, human

Identifiers

PMID34995294
PMCPMC8740962
OpenAlexW4205733040

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.